Determination of doravirine in human plasma using liquid–liquid extraction and HPLC–MS/MS
Abstract
Aim: A method to quantitate doravirine (MK-1439) in human plasma has been developed to support human clinical trials designed to evaluate the safety, pharmacokinetics and efficacy of the compound. Methodology & results: The analyte was extracted using liquid–liquid extraction, separated on a reverse phase HPLC column, and detected on an API-4000 mass spectrometer using a Turbo-Ion spray source in positive ionization mode coupled with multiple reaction monitoring mode was used for quantification. The dynamic range for the assay was 0.02–10 ng/ml using 100 μl of human plasma. Conclusion: The assay was found to be sensitive, selective and reproducible and applied to support the doravirine clinical development program.
Papers of special note have been highlighted as: • of interest; •• of considerable interest
References
- 1. Safety, tolerability and pharmacokinetics of Doravirine, a novel HIV non-nucleoside reverse transcriptase inhibitor, after single and multiple doses in healthy subjects. Antivir. Ther. 20(4), 397–405 (2015).
- 2. . Non-nucleoside reverse transcriptase inhibitors: a review on pharmacokinetics, pharmacodynamics, safety and tolerability. J. Int. AIDS Soc. 16(1), 1–14 (2013).
- 3. . In vitro resistance selection with doravirine (MK-1439), a novel nonnucleoside reverse transcriptase inhibitor with distinct mutation development pathways. Antimicrob. Agents Chemother. 59(1), 590–598 (2015).
- 4. Doravirine suppresses common nonnucleoside reverse transcriptase inhibitor-associated mutants at clinically relevant concentrations. Antimicrob. Agents Chemother. 60(4), 2241–2247 (2016).
- 5. A randomized, double-blind, placebo-controlled, short-term monotherapy study of doravirine in treatment-naive HIV-infected individuals. AIDS 30(1), 57–63 (2016).
- 6. Forty-eight-week efficacy and safety and early CNS tolerability of doravirine (MK-1439), a novel NNRTI, with TDF/FTC in ART-naive HIV-positive patients. J. Int. AIDS Soc. 17(4S3), 19532–19533 (2014). •• Two Phase III trials demonstrated noninferior efficacy to ritonavir-boosted darunavir and efavirenz with a superior neuropsychiatric profile compared with efavirenz and a more favorable lipid profile compared with both ritonavir-boosted darunavir and efavirenz.
- 7. Bristol-Myers Squibb Company. Sustiva (efavirenz) prescribing information. Bristol-Myers Squibb Company. NJ, USA (2010).
- 8. US Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. DC, USA (2015). http://aidsinfo.nih.gov/guidelines • doravirine may be effective for patients who do not tolerate efavirenz. Efavirenz has a number of side effects, including psychiatric and CNS-related issues, that have caused efavirenz to be downgraded to an alternative therapy, according to US Department of Health and Human Services guidelines.
- 9. The effect of single and multiple doses of rifampin on the pharmacokinetics of doravirine in healthy subjects. Clin. Drug Investig. 37(7), 659–667 (2017).
- 10. The effect of food on doravirine bioavailability: results from pharmacokinetic studies in healthy subjects. Clin. Drug Investig. 37(6), 571–579 (2017).
- 11. . Determination of a beta (3)-agonist in human plasma by LC/MS/MS with semi-automated 48-well diatomaceous earth plate. J. Pharm. Biomed. Anal. 26(3), 357–365 (2001).
- 12. US FDA, Center for Drug Evaluation and Research. Guidance for Industry Bioanalytical Method Validation USDOHaHS, Center for Veterinary Medicine (2001). www.fda.gov/Downloads/Drugs/Guidance/Ucm070107.Pdf
- 13. . Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC−MS/MS. Anal. Chem. 75, 3019–3030 (2003). • Careful assessment of matrix effect is an important part of bioanalytical assay. The precision and accuracy assessment in different lots of matrix would lead more reliable and robust assay.
